A 6-year-old child with known epilepsy presents with status epilepticus. Lorazepam was administered 10 minutes ago but seizures persist. What is the preferred second-line agent for refractory status epilepticus in this child?

Explanation

## Second-Line Management of Refractory Status Epilepticus **Key Point:** After benzodiazepine failure, fosphenytoin is the preferred second-line agent in pediatric status epilepticus due to superior safety profile and faster onset compared to phenytoin. ### Why Fosphenytoin Over Phenytoin? **High-Yield:** Fosphenytoin is a prodrug of phenytoin with critical advantages: - Faster IV infusion rate (up to 150 mg/min vs. 50 mg/min for phenytoin) - No risk of tissue necrosis or purple glove syndrome (can be given through peripheral IV) - Better tolerability; no local irritation - Faster onset of action (~10–15 minutes) - Equivalent efficacy to phenytoin **Dosing in Children:** - IV: 15–20 mg/kg PE (phenytoin equivalents) at 3 mg PE/kg/min - Can be repeated once if seizures persist ### Refractory Status Epilepticus Algorithm ```mermaid flowchart TD A[Status Epilepticus + Lorazepam Failed]:::outcome --> B{Second-line choice?}:::decision B -->|Preferred| C[Fosphenytoin 15-20 mg/kg PE IV]:::action B -->|Alternative| D[Levetiracetam 30-60 mg/kg IV]:::action B -->|Alternative| E[Valproic acid 15-20 mg/kg IV]:::action C --> F{Seizures controlled?}:::decision D --> F E --> F F -->|Yes| G[Admit, continuous monitoring]:::action F -->|No| H[Third-line: Phenobarbital or Propofol]:::urgent H --> I[ICU admission, intubation]:::urgent ``` **Clinical Pearl:** Fosphenytoin is preferred over phenytoin in pediatrics because it can be given through peripheral IV lines and infused faster, reducing the risk of extravasation injury — a critical advantage in the emergency setting. **Mnemonic:** **FOSPHENYTOIN Superiority** — **F**aster infusion, **O**ver phenytoin, **S**afer (no necrosis), **P**eripheral IV safe, **H**igher infusion rate, **E**arlier onset, **N**o purple glove, **Y**ield better outcomes, **T**issue-safe, **O**ptimal choice, **I**V-friendly, **N**o extravasation risk. ### Second-Line Agent Comparison | Agent | Onset | Infusion Rate | Safety | Use | |-------|-------|---------------|--------|-----| | **Fosphenytoin** | 10–15 min | 150 mg/min | Peripheral IV safe | **Preferred** | | **Levetiracetam** | 10–15 min | Rapid IV push | Very safe | Alternative | | **Valproic acid** | 5–10 min | Rapid IV | Hepatotoxicity risk | Alternative | | **Phenytoin** | 10–20 min | 50 mg/min max | Central line needed | Avoid if fosphenytoin available | **Warning:** ~~Phenytoin~~ should not be used if fosphenytoin is available due to risk of tissue necrosis, purple glove syndrome, and slower infusion rate. [cite:Indian Academy of Pediatrics Guidelines on Pediatric Emergencies]